skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
VEGFR2-169 Peptide Vaccine (Code C74090)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: VEGFR2-169 Peptide Vaccine

Definition: A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.

Label: VEGFR2-169 Peptide Vaccine

NCI Thesaurus Code: C74090 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL383528  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
VEGFR2-169 Peptide Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 589327
PDQ Open Trial Search ID 589327 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C74090
Legacy_Concept_Name VEGFR2-169_Peptide_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom